Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT00396071
- Locations
- 🇩🇪
Diabetes Zentrum Bad Lauterberg, Bad Lauterberg, Germany
🇨🇭Novartis Pharmaceuticals, Basel, Switzerland
Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis
Phase 1
Completed
- Conditions
- Iron OverloadHereditary Hemochromatosis
- Interventions
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 49
- Registration Number
- NCT00395629
- Locations
- 🇺🇸
Three Medical Park, Columbia, South Carolina, United States
🇺🇸Rochester General Hospital, Rochester, New York, United States
🇺🇸Ohio State University Medical Center, Columbus, Ohio, United States
A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.
Phase 2
Completed
- Conditions
- Transfusional Iron Overloadβ-thalassemia MajorPediatric Rare Anemia
- Interventions
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00390858
- Locations
- 🇮🇹
Novartis Investigative Site, Torino, Italy
Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis
Phase 3
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 517
- Registration Number
- NCT00388505
- Locations
- 🇮🇹
Novartis Investigator Site, Genoa, Italy
🇬🇧Novartis Investigative Site, Sheffield, United Kingdom
🇺🇸University of Rochester, Rochester, New York, United States
Safety of Artemether - Lumefantrine, and Other Malaria Drugs and Their Effect on the Auditory Function
Phase 4
Terminated
- Conditions
- MalariaFalciparum
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 265
- Registration Number
- NCT00386750
Study To Assess Long Term Safety Of Pazopanib
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 188
- Registration Number
- NCT00387205
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
Phase 1
Completed
- Conditions
- Chronic Myelogenous LeukemiaAcute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
- Interventions
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT00384228
- Locations
- 🇯🇵
Novartis Investigative Site, Tokyo, Japan
Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 335
- Registration Number
- NCT00383578
- Locations
- 🇩🇪
Investigative Centers, Nurnberg, Germany
🇨🇭Novartis Pharmaceuticals, Basel, Switzerland
Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1179
- Registration Number
- NCT00382096
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload
- First Posted Date
- 2006-09-22
- Last Posted Date
- 2015-03-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT00379483
- Locations
- 🇮🇹
Novartis Investigative Site, Torino, Italy
© Copyright 2025. All Rights Reserved by MedPath